

Patricia R Freeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4669440/publications.pdf>

Version: 2024-02-01

67
papers

1,511
citations

331670

21
h-index

330143

37
g-index

67
all docs

67
docs citations

67
times ranked

1575
citing authors

#	ARTICLE	IF	CITATIONS
1	Changing Trends in Drug Overdose Mortality in Kentucky: An Examination of Race and Ethnicity, Age, and Contributing Drugs, 2016-2020. Public Health Reports, 2023, 138, 131-139.	2.5	7
2	Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky. Journal of Rural Health, 2023, 39, 186-196.	2.9	3
3	Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky. Journal of Rural Health, 2022, 38, 93-99.	2.9	2
4	New means, new measures: assessing prescription drug-seeking indicators over 10 years of the opioid epidemic. Addiction, 2022, 117, 195-204.	3.3	4
5	A qualitative study on pharmacy policies toward over-the-counter syringe sales in a rural epicenter of US drug-related epidemics. Harm Reduction Journal, 2022, 19, 1.	3.2	8
6	Broadband internet subscription rates and opioid prescribing via telemedicine during the COVID-19 pandemic. Journal of Rural Health, 2022, 38, 900-907.	2.9	3
7	Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology. Pain and Therapy, 2022, 11, 133-151.	3.2	3
8	Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018. Journal of Rural Health, 2021, 37, 23-28.	2.9	3
9	Primary care clinician and community pharmacist perceptions of deprescribing. Journal of the American Geriatrics Society, 2021, 69, 1686-1689.	2.6	8
10	“Doctor and pharmacy shopping”: A fading signal for prescription opioid use monitoring?. Drug and Alcohol Dependence, 2021, 221, 108618.	3.2	10
11	Characterization of gabapentin use in Kentucky after reclassification as a Schedule V controlled substance. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e86-e92.	1.5	0
12	Rural-urban differences in hospitalizations for opioid use-associated infective endocarditis in Kentucky, 2016-2019. Journal of Rural Health, 2021, , .	2.9	0
13	Trends in Drug Overdose Mortality Rates in Kentucky, 2019-2020. JAMA Network Open, 2021, 4, e2116391.	5.9	11
14	Predictors of chronic opioid therapy in Medicaid beneficiaries with HIV who initiated antiretroviral therapy. Scientific Reports, 2021, 11, 15503.	3.3	0
15	Letter to the Editor regarding: Medicaid prescription limits and their implications for naloxone accessibility (by Roberts et al., 2021). Drug and Alcohol Dependence, 2021, 226, 108888.	3.2	1
16	Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Pain Physician, 2021, 24, E249-E256.	0.4	1
17	Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven. Health Informatics Journal, 2020, 26, 787-802.	2.1	8
18	Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Research in Social and Administrative Pharmacy, 2020, 16, 1306-1308.	3.0	6

#	ARTICLE	IF	CITATIONS
19	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	3.2	50
20	Community engagement to implement evidence-based practices in the HEALing communities study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108326.	3.2	38
21	Universityâ€“pharmacy partnerships for COVID-19. <i>Science</i> , 2020, 369, 1441-1441.	12.6	0
22	When Prescribing Isnâ€™t Enough â€” Pharmacy-Level Barriers to Buprenorphine Access. <i>New England Journal of Medicine</i> , 2020, 383, 703-705.	27.0	41
23	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.2	50
24	Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. <i>International Journal of Drug Policy</i> , 2020, 85, 102701.	3.3	64
25	Association between state Medicaid expansion status and naloxone prescription dispensing. <i>Health Services Research</i> , 2020, 55, 239-248.	2.0	12
26	Appalachian disparities in tobacco cessation treatment utilization in Medicaid. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 5.	2.2	3
27	Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 246-252.	0.9	33
28	Communication between pharmacists and primary care physicians in the midst of a U.S. opioid crisis. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 974-985.	3.0	14
29	Trends and Patterns of Opioid Analgesic Prescribing: Regional and Ruralâ€“Urban Variations in Kentucky From 2012 to 2015. <i>Journal of Rural Health</i> , 2019, 35, 97-107.	2.9	36
30	Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012â€“2017. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107606.	3.2	1
31	Co-prescription network reveals social dynamics of opioid doctor shopping. <i>PLoS ONE</i> , 2019, 14, e0223849.	2.5	12
32	Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States. <i>JAMA Network Open</i> , 2019, 2, e196215.	5.9	73
33	Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 379-382.	1.5	5
34	Obstetrician/Gynecologist Perception of Prescription Drug Monitoring Program Effectiveness [15]. <i>Obstetrics and Gynecology</i> , 2019, 133, 99S-99S.	2.4	1
35	Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 754-760.	3.0	40
36	Patterns and predictors of chronic opioid use in older adults: A retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0210341.	2.5	28

#	ARTICLE	IF	CITATIONS
37	Statin Use and Gastrointestinal Hemorrhage: A Large Retrospective Cohort Study. American Journal of Cardiovascular Drugs, 2019, 19, 65-74.	2.2	17
38	Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug and Alcohol Dependence, 2018, 184, 26-32.	3.2	50
39	Rapid Expansion of the Opioid Ecosystem: National Implications for Prescriber-Pharmacist Communication. American Journal of Preventive Medicine, 2018, 55, 656-661.	3.0	13
40	The changing landscape of naloxone availability in the United States, 2011 - 2017. Drug and Alcohol Dependence, 2018, 191, 361-364.	3.2	72
41	Predicting Substance Use Disorder in ADHD Patients using Long-Short Term Memory Model. , 2018, 2018, 49-50.		3
42	Pharmacists' role in harm reduction: a survey assessment of Kentucky community pharmacists' willingness to participate in syringe/needle exchange. Harm Reduction Journal, 2018, 15, 4.	3.2	23
43	Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S28-S33.	1.5	69
44	Development and delivery of a pharmacist training program to increase naloxone access in Kentucky. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S118-S122.	1.5	24
45	Prescription drug monitoring program utilization in Kentucky community pharmacies. Pharmacy Practice, 2015, 13, 540.	1.5	17
46	Implementation of personalized medicine services in community pharmacies: Perceptions of independent community pharmacists. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 510-517.	1.5	54
47	Law Enforcement Perceptions of a Prescription Drug Monitoring Programme. International Journal of Police Science and Management, 2014, 16, 288-296.	1.3	2
48	Kentucky pharmacists' opinions of the potential reclassification of pseudoephedrine as a legend drug. Journal of the American Pharmacists Association: JAPhA, 2014, 54, 397-405.	1.5	2
49	Community Pharmacist Characteristics Associated With Use Of A Prescription Drug Monitoring Program. Value in Health, 2014, 17, A15.	0.3	0
50	Kentucky Physician Opinions Of The Potential Reclassification Of Pseudoephedrine As A Legend Drug. Value in Health, 2013, 16, A249.	0.3	0
51	Immunization Training: Right or Privilege?. American Journal of Pharmaceutical Education, 2012, 76, 57.	2.1	11
52	Pseudoephedrine Sales and Seizures of Clandestine Methamphetamine Laboratories in Kentucky. JAMA - Journal of the American Medical Association, 2012, 308, 1524.	7.4	3
53	DR2 The Relationship Between Pseudoephedrine Sales and Clandestine Methamphetamine Labs. Value in Health, 2012, 15, A6-A7.	0.3	0
54	PHP93 Impact of Prescription Monitoring Programs on Pharmacists' Controlled Substance Dispensing Behavior. Value in Health, 2012, 15, A29-A30.	0.3	2

#	ARTICLE	IF	CITATIONS
55	PMH82 Do Sales of Pseudoephedrine Predict Methamphetamine-Related Hospitalizations?. Value in Health, 2012, 15, A96-A97.	0.3	0
56	Independent community pharmacist interest in participating in community pharmacy research networks. Journal of the American Pharmacists Association: JAPhA, 2011, 51, 727-738.	1.5	24
57	Eliciting Willingness to Pay Without Bias: Evidence from a Field Experiment. Economic Journal, 2008, 118, 114-137.	3.6	273
58	Teriparatide: A Novel Agent That Builds New Bone. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 535-537.	1.5	5
59	Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma. Pharmacoeconomics, 2002, 20, 257-265.	3.3	45
60	Anakinra Shows Promise for Treating Patients With Rheumatoid Arthritis. Journal of the American Pharmacists Association, 2002, 42, 660-662.	0.5	7
61	Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. Journal of Health Economics, 2001, 20, 441-457.	2.7	170
62	Biotechnology Update: Pharmacogenetics and Pharmacogenomics: Using Genetic Information to Guide Therapeutic Decision Making. Journal of the American Pharmacists Association, 2001, 41, 475-476.	0.5	5
63	Biotechnology Update: Pharmacogenomics: Opening New Vistas in Pharmacotherapy. Journal of the American Pharmacists Association, 2001, 41, 629-630.	0.5	3
64	Monoclonal Antibody Approved for Treatment of Crohn's Disease. Journal of the American Pharmacists Association, 1998, 38, 770-772.	0.5	1
65	Topical Peptide Growth Factors, Wound Repair. American Pharmacy, 1993, 33, 18-19.	0.2	0
66	Epidermal Growth Factor Augments Reactivity to Angiotensin II in the Rat Pulmonary Circulation. The American Review of Respiratory Disease, 1989, 140, 821-824.	2.9	11
67	Polyamines and Epidermal Growth Factor in Monocrotaline-induced Pulmonary Hypertension. The American Review of Respiratory Disease, 1989, 140, 1463-1466.	2.9	26